NCT05035277View on ClinicalTrials.gov

AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation

PHASE3RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

December 4, 2021

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Aortic Stenosis
Interventions
DRUG

Acetylsalicylic acid

Acetylsalicylic acid 75 mg once daily is the current standard-of-care in TAVI patients without other indications for anticoagulation therapy.

DRUG

Apixaban

Standard dose apixaban will be one of the options for the patients in the experimental arm.

DRUG

Rivaroxaban

Standard dose rivaroxaban will be one of the options for the patients in the experimental arm.

DRUG

Edoxaban

Standard dose edoxaban will be one of the options for the patients in the experimental arm.

Trial Locations (3)

5021

NOT_YET_RECRUITING

Haukeland University Hospital, Bergen

0424

NOT_YET_RECRUITING

Oslo Univesity Hospital - Ullevål, Oslo

0772

RECRUITING

Oslo University Hospital - Rikshospitalet, Oslo

All Listed Sponsors
collaborator

University of Oslo

OTHER

lead

Oslo University Hospital

OTHER